BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

If we take a look at Pfizer’s top products for 2024, we can observe that the sales from their COVID vaccine, Comirnaty, dropped more than 50% vs. 2023 due to a decrease in vaccinations globally ...

Pfizer (PFE) announced it does not anticipate significant changes to U.S. vaccine policy under the incoming Trump administration, despite vaccine skeptic Robert F. Kennedy Jr.’s nomination to ...

The settlements will see BioNTech pay $791.5 million to NIH and $467 million to Penn, with Pfizer (PFE), its vaccine partner, reimbursing part of these payments.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Pfizer said it anticipates no major vaccine policy changes under Trump in 2025. CEO Albert Bourla expressed willingness to work with RFK Jr. if confirmed to run the Department of Health and Human ...

Council of the Americas, with the support of Pfizer, convenes high-level roundtable discussions across Latin America.